RE: Update27 Apr 2026 18:50
As of April 2026, Renalytix is scaling the distribution and operational capacity of its kidneyintelX.dkd (KidneyIntelX) diagnostic test in the U.S. and preparing for European expansion. The test is used to manage diabetic kidney disease (DKD) risk.
Key 2026 distribution milestones include:
. New York Laboratory Expansion: A new, state-of-the-art facility in New York is now operational, increasing testing capacity by more than 3.5x and providing infrastructure to support over 100,000 tests annually.
. U.S. Expansion: KidneyIntelX is being deployed across large physician group practices and health systems in the eastern and western US.
. EMR Integration: Several new U.S. healthcare provider groups were integrated with Electronic Medical Record (EMR) test ordering capabilities in early 2026, simplifying the ordering process for clinicians.
. European Launch Plans: Renalytix submitted the technical file for CE marking in April 2026, with approval expected in Q3 2026. Initial testing in Europe is slated to start at the Steno Diabetes Center in Q4 2026.